The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s GLP-1 receptor agonist market report forecasts the GLP-1 receptor agonist market size to grow to $15.54 Billion by 2027, with a CAGR (compound annual growth rate) of more than 4%.

Learn More On The GLP-1 Receptor Agonist Market Report 2023 – https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

GLP-1 Receptor Agonist Market Size Forecast
The global GLP-1 receptor agonist market is expected to grow from $12.48 billion in 2022 to $13.07 billion in 2023 at a compound annual growth rate (CAGR) of 4.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The global GLP-1 receptor agonist market is expected to reach $15.54 billion in 2027 at a CAGR of 4.4%.

North America held the largest GLP-1 receptor agonist market share, and Asia-Pacific was the fastest-growing region in 2022.

Key GLP-1 Receptor Agonist Market Driver ­– Rise In The Prevalence Of Diabetes
According to the International Diabetes Federation, a Belgium-based umbrella organisation of over 230 national diabetes associations, the global population living with diabetes in December 2021 will be approximately 537 million adults, with a projected increase to 643 million by 2030. As a result, the increasing prevalence of diabetes is propelling the GLP-1 receptor agonist market.

Request for A Sample Of The Global GLP-1 Receptor Agonist Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

Key GLP-1 Receptor Agonist Market Trend – Product Innovations
Major players in the GLP-1 receptor agonist market are concentrating on finding novel solutions to enhance their positions. For example, in May 2022, Eli Lilly and firm, a US-based pharmaceutical firm that develops medications to improve people’s lives, will debut the FDA-approved novel Mounjaro, a GIP and GLP-1 receptor agonist. It is carefully created using a single molecule that activates the incretin hormones GIP and GLP-1 receptors in the body. It is offered in 6 doses as a pen auto-injector with a pre-attached, concealed needle that patients do not need to handle or see.

GLP-1 Receptor Agonist Market Segment
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users

GLP-1 Receptor Agonist Market Major Players and Strategies
Major players in the GLP-1 receptor agonist market are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., 9 Meters Biopharma Inc., Intarcia Therapeutics Inc., Amylin Pharmaceuticals Inc., and PegBio Co. Ltd.

Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., 9 Metres Biopharma Inc., Intarcia Therapeutics Inc., Amylin Pharmaceuticals Inc., and PegBio Co. Ltd.

The GLP-1 Receptor Agonist Global Market Report 2023 covers regional data on GLP-1 receptor agonist market size, GLP-1 receptor agonist market trends and drivers, opportunities, strategies, and GLP-1 receptor agonist market competitor analysis. The countries covered in the GLP-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

A GLP-1 receptor agonist is a type of medicine that promotes insulin release when blood glucose levels are high and decreases glucagon production when blood glucose levels are low. They are prescribed to patients with type 2 diabetes.

View More Reports Related To The GLP-1 Receptor Agonist Market –
1-Decanol Global Market Report 2023
AntiParkinson Drugs Global Market Report 2023
Antacids Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: